INTRODUCTION: Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma with a poorly understood molecular etiology. We implemented a comprehensive deep sequencing approach to identify mutations in the tumor DNA from a cohort of patients treated at our institution over the past 15 years. Our results indicate mutations that may constitute therapeutic targets in MCC. METHODS: Five patients were treated for MCC within the study interval. Patients with adequate tissue (n = 4), positive neuroendocrine differentiation (chromogranin, synaptophysin, and cytokeratin 20), and histopathological confirmation of MCC were included in the study. DNA was extracted from archival tumor tissue samples and analyzed by massively parallel sequencing using a targeted, multiplex PCR approach followed by semiconductor sequencing. RESULTS: We demonstrate high-penetrance nonsense mutations in PDE4DIP (n = 4) as well as various missense mutations in the DNA damage response (PRKDC, AURKB, ERCC5, ATR, and ATRX) and epigenetic modulating enzymes (MLL3). CONCLUSION: We describe several mutations in potential disease-relevant genes and pathways. These targets should be evaluated in a larger cohort to determine their role in the molecular pathogenesis of MCC.
INTRODUCTION:Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma with a poorly understood molecular etiology. We implemented a comprehensive deep sequencing approach to identify mutations in the tumor DNA from a cohort of patients treated at our institution over the past 15 years. Our results indicate mutations that may constitute therapeutic targets in MCC. METHODS: Five patients were treated for MCC within the study interval. Patients with adequate tissue (n = 4), positive neuroendocrine differentiation (chromogranin, synaptophysin, and cytokeratin 20), and histopathological confirmation of MCC were included in the study. DNA was extracted from archival tumor tissue samples and analyzed by massively parallel sequencing using a targeted, multiplex PCR approach followed by semiconductor sequencing. RESULTS: We demonstrate high-penetrance nonsense mutations in PDE4DIP (n = 4) as well as various missense mutations in the DNA damage response (PRKDC, AURKB, ERCC5, ATR, and ATRX) and epigenetic modulating enzymes (MLL3). CONCLUSION: We describe several mutations in potential disease-relevant genes and pathways. These targets should be evaluated in a larger cohort to determine their role in the molecular pathogenesis of MCC.
Authors: Boban M Erovic; Ayman Al Habeeb; Luke Harris; David P Goldstein; Danny Ghazarian; Jonathan C Irish Journal: Head Neck Date: 2012-02-06 Impact factor: 3.147
Authors: Asha Balakrishnan; Fonnet E Bleeker; Simona Lamba; Monica Rodolfo; Maria Daniotti; Aldo Scarpa; Angela A van Tilborg; Sieger Leenstra; Carlo Zanon; Alberto Bardelli Journal: Cancer Res Date: 2007-04-15 Impact factor: 12.701
Authors: Kathryn Wilkinson; Elvira R P Velloso; Luiz Fernando Lopes; Charles Lee; Jon C Aster; Margaret A Shipp; Ricardo C T Aguiar Journal: Blood Date: 2003-08-07 Impact factor: 22.113
Authors: Paul William Harms; Pankaj Vats; Monique Elise Verhaegen; Dan R Robinson; Yi-Mi Wu; Saravana Mohan Dhanasekaran; Nallasivam Palanisamy; Javed Siddiqui; Xuhong Cao; Fengyun Su; Rui Wang; Hong Xiao; Lakshmi P Kunju; Rohit Mehra; Scott A Tomlins; Douglas Randall Fullen; Christopher Keram Bichakjian; Timothy M Johnson; Andrzej Antoni Dlugosz; Arul M Chinnaiyan Journal: Cancer Res Date: 2015-08-03 Impact factor: 12.701